Givaudan ends research collaboration with Redpoint
April 15, 2009
by Jeff Gelski
EWING, N.J. — Givaudan, Vernier, Switzerland, has terminated its research and development collaboration and licensing agreement with Redpoint Bio Corp. The agreement signed in March of 2007 was designed to discover and develop sweetener and savory enhancers and bitter blocker compounds.
"While we are disappointed with the conclusion of our partnership with Givaudan, we believe that Redpoint’s technology platform continues to provide opportunities to discover new products for both the food and beverage and pharmaceutical industries," said Dr. Ray Salemme, Ph. D., chief executive officer of Ewing-based Redpoint Bio. "We continue to advance our taste modulation discovery programs, in addition to investigating potential therapeutic applications for our compounds for the treatment of diabetes and obesity.
"We recognize that due to strategic changes in focus, Givaudan was not able to continue with our collaboration. However, we continue to maintain a positive relationship with Givaudan, the world’s leading company in the flavors and fragrances industry."